Medco Research's Adenoscan approved May 18; Fujisawa will market product.
This article was originally published in The Gray Sheet
Executive Summary
MEDCO RESEARCH ADENOSCAN APPROVED MAY 18 by FDA as an injectable coronary vasodilator to be used as "an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately" to undergo stress testing for diagnosis of coronary artery disease. The adenosine product is composed of the endogenous naturally occurring nucleoside 6-amino-9-beta-D-ribofuranosyl-9-H-purine. FDA deemed the product "approvable" April 18.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.